Sativex Associated With Behavioral-Relapse Prevention Strategy as Treatment for Cannabis Dependence A Case Series.
Cannabis is the most commonly used illicit drug a substantial minority of users develop dependence. The current lack of pharmacological treatments for cannabis dependence warrants the use of novel approaches and further investigation of promising pharmacotherapy. In this case series, we assessed the use of self-titrated dosages of Sativex (11, Δ-tetrahydrocannabinol THCcannabidiol CBD combination) and motivational enhancement therapy and cognitive behavioral therapy (METCBT) for the treatment of cannabis dependence among 5 treatment-seeking community-recruited cannabis-dependent subjects. Participants underwent a 3-month open-label self-titration phase with Sativex (up to 113.4 of THC105 mg of CBD) and weekly METCBT, with a 3-month follow-up. Sativex was well-tolerated by all participants (average dosage 77.5 THC71.7 mg CBD). The combination of Sativex and METCBT reduced the amount of cannabis use and progressively reduced craving and withdrawal scores. THCCBD metabolite concentration indicated reduced cannabis use and compliance with medication. In summary, this pilot study found that with Sativex in combination with METCBT reduced cannabis use while preventing increases in craving and withdrawal in the 4 participants completing the study. Further systematic exploration of Sativex as a pharmacological treatment option for cannabis dependence should be performed.